Pancreatic Cancer Medications
Here's a list of the approved drugs to treat pancreatic cancer. Click on any of the medications for more info on indications, dosing and side effects.
Quick Filter
*generic version available
E experimental
Chemotherapy Medications
Immunotherapy Medications
Targeted Therapy Medications
Chemotherapy Medications More >>
| DRUG Chemotherapy |
|---|
| GENERIC NAME Multiple |
|
DRUG INDICATION
Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here. |
Immunotherapy Medications More >>
| DRUG Keytruda |
|---|
| GENERIC NAME pembrolizumab |
|
DRUG INDICATION
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. |
Targeted Therapy Medications More >>
| DRUG Lynparza |
|---|
| GENERIC NAME olaparib |
|
DRUG INDICATION
Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations. |
| DRUG Rozlytrek |
|---|
| GENERIC NAME entrectinib |
|
DRUG INDICATION
Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer. |
| DRUG Sutent |
|---|
| GENERIC NAME sunitib |
|
DRUG INDICATION
Sutent is a kinase inhibitor approved for treatment of gastrointestinal stromal tumor, pancreatic neuroendocrine tumors and advanced kidney cancer (renal cell carcinoma), and for adjuvant treatment of high-risk kidney cancer after surgery. |
| DRUG Tarceva |
|---|
| GENERIC NAME erlotinib |
|
DRUG INDICATION
Tarceva is an EGFR inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations, and as first-line therapy for locally advanced, inoperable or metastatic pancreatic cancer, in combination with gemcitabine chemotherapy. |
| DRUG Vitrakvi |
|---|
| GENERIC NAME larotrectinib |
|
DRUG INDICATION
Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions. |
